Kerala Public Service Commission invites applications for faculty posts, Check All Details

The Kerala Public Service Commission (KPSC) has invited online application for Faculty posts on Direct Recruitment Basis in Medical Education Department. The selection will be done based on the written exam and interview.

KPSC is a body created by the Constitution of India. The Commission advise the Government on all matters relating to civil services referred to it under Article 320 (3) of the Constitution and publish notifications inviting applications for selection to various posts as per the requisitions of the appointing authorities, conduct written test and/or practical tests, physical efficiency test and interview, prepare ranked list based on the performance of the candidates and advise candidates for appointment strictly based on their merit and observing the rules of reservation as and when vacancies are reported. The Head Office of the Kerala Public Service Commission is situated at Pattom, Thiruvananthapuram, the State Capital.

For more information, click on the link below:

Powered by WPeMatico

Opioid prescribing standards changed practices in British Columbia, but with caveats

In an effort to curb misuse of opioids and prevent overdose deaths, the College of Physicians and Surgeons of British Columbia released a legally enforceable practice standard, “Safe Prescribing of Drugs with Potential for Misuse/Diversion,” in 2016. This document limited the prescribing of opioids for chronic noncancer pain (CNCP) with specific prescribing practices that clinicians were obligated to follow.

Powered by WPeMatico

Failure to focus on COVID suppression led to avoidable UK deaths, says expert

Early in the COVID-19 pandemic, the failure of UK government advisers to follow World Health Organization (WHO) advice and emerging evidence from East Asia that suppression could bring the virus under control quickly led to avoidable UK deaths, argues an expert in The BMJ.

Powered by WPeMatico

Talk therapy on the rise, psychiatric meds used less often

More talk and fewer pills are being employed to help Americans maintain their mental health, a new study says.

Powered by WPeMatico

AI tool uses selfies to predict biological age and cancer survival

Doctors often start exams with the so-called “eyeball test”—a snap judgment about whether the patient appears older or younger than their age, which can influence key medical decisions.

Powered by WPeMatico

Five evidence-based ways to manage chronic stress—by an expert in behavioral psychology

Spend too long on social media and you might start to hear the term “cortisol face” used to describe someone with supposedly puffy eyes or cheeks. The phrase describes the physical signs that some believe result from prolonged stress, particularly elevated levels of the hormone cortisol. It’s often used to encourage people to do something about their stress levels.

Powered by WPeMatico

Centre Sanctions Rs 500 Crore for 1000-bed expansion at Kalawati Saran Children’s Hospital

Delhi: In a major boost to pediatric healthcare, the national capital is set to host the country’s largest child medical science hospital and research centre, with the government earmarking a Rs 500 crore budget for its development. The hospital’s expansion is expected to ease the burden on existing pediatric facilities, enhance healthcare services for children.

The expansion project will take place at Kalawati Saran Children’s Hospital, where a state-of-the-art building will be established within the hospital premises. The project will not only expand clinical services but also focus on cutting-edge research in childhood diseases, making it a center of excellence for both treatment and innovation.

Also Read: 600-bed facility coming up at Chacha Nehru Bal Chikitsalay in Delhi

Speaking to Zee News India, the officials said that cancer, heart disease, neurological disorders, and other types of complex diseases will be treated in the centre. Along with this, the ICU, the operation theatre, and the diagnostic centre will also be built here for children. Along with this, there will be a facility of 1 thousand beds here.

Kalawati Saran Children’s Hospital, located within the campus of Lady Hardinge Medical College in New Delhi, is a renowned multi-speciality pediatric institution. It was founded and initially headed by Dr. Sheila Singh Paul, a pioneering figure in child healthcare in India. The upcoming transformation will elevate it to the forefront of child healthcare in the region.  

Also Read: Lady Hardinge Medical College to upgrade many Departments to Super-Specialty

Medical Dialogues had previously reported that after the completion of the first phase of redevelopment, the Lady Hardinge Medical College is all set for the second phase of expansion. Lady Hardinge Medical College is making arrangements to convert the existing departments into super-speciality wards in an attempt to improve medical services. Medical, obstetric and gynecological, surgical, orthopaedics, and nuclear medicine departments are soon to be upgraded accordingly. Kalawati Saran Children’s Hospital is also undergoing redevelopment and expansion.

Powered by WPeMatico

USFDA successfully completes inspection at Solara Ambernath facility

Chennai: Solara Active Pharma Sciences Limited, an Active
Pharmaceutical Ingredient provider, has announced that its multi-product manufacturing facility at
Ambernath, Maharashtra has successfully completed the inspection carried out by the US Food and Drug
Administration (US FDA).

The inspection established that the site is in an “Acceptable State of Compliance”
with Zero Form 483 inspectional observations from US FDA.
The Agency with their designated
investigator inspected the facility from 5
th to 9
th May 2025. 
Commenting on the Inspection Outcome, Sandeep Rao, MD & CEO said, “We are very happy with the
successful inspection outcome of our Ambernath API site with Zero 483 inspectional observations. This is the
third (3rd) consecutive successful inspection outcome, with Zero 483 inspectional observations, across the
Solara network of manufacturing facilities. The inspection outcome demonstrates our commitment to
regulatory excellence at our global manufacturing sites and relentless focus on world-class quality and
compliance, which remains a key pillar of our growth strategy. We stay committed to exhibit the highest level
of compliance and constant focus on world-class quality with the validated quality systems established across
Solara’s manufacturing network.”

An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

The Ambernath multi-product API manufacturing facility was established in the year 2004 and is equipped
with appropriate infrastructure to include several independent production blocks and related packaging
sections. This site is inspected by various Regulatory Authorities including US FDA, EDQM, WHO, PMDA,
and KFDA.
Solara Active Pharma Sciences Ltd is a global API manufacturer supported by
state-of-the-art R&D and manufacturing facilities. With 6 manufacturing facilities and an R&D Centre, Solara offers a
basket of diversified Commercial APIs and Contract manufacturing services. Its API facilities are approved by
various international regulatory agencies including the USFDA, EDQM, MFDS, WHO, PMDA etc.
Read also: USFDA concludes inspection at Solara Active Pharma Sciences Vizag facility with Zero 483 inspectional observations

Powered by WPeMatico

13 AYUSH doctors appointed to take action against misleading ads

Vijayawada: As many as 13 government AYUSH (Ayurveda, Yoga, Unani, Siddha, and Homoeopathy) doctors have been appointed by the Andhra Pradesh government to take action against misleading advertisements related to traditional medicine.  

The decision, announced by Health Minister Y. Satya Kumar Yadav, aims to curb false medical claims under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.

Minister Yadav asked the 13 doctors to take action against any person found involved in publishing or preparing the content, as per the Act. He also instructed the police officers to register the complaints without delay.

Also read- India Highlights Advances in Traditional Medicine at INTRACOM 2024

Until now, only one official was responsible for monitoring such ads across the state. With this new step, each of the 13 selected doctors will be assigned to each district. 

The move comes after the Supreme Court took serious note of false medical claims and called for a redressal mechanism in all States. Following the apex court order, the Minister selected the Ayush doctors, intending to improve the surveillance on fake advertisements in the field of traditional medicines.

With regard to fake claims in the field of allopathic medicine, the State government had already instructed all drug inspectors to keep a watch on advertisements. At present, 49 drug inspectors are working in the State, keeping a tab on misleading claims regarding the use of allopathic medicines.

The Hindu has reported that the Act prohibits publishing of any such advertisement that promotes certain drugs to prevent miscarriages or conception in women or that claims to improve the capacity of human beings for sexual pleasure or correction of menstrual disorders in women. Under the Act, there is a provision for a punishment of up to six years or a fine or both.

Medical Dialogues had previously reported that the World Health Organisation (WHO) announced the 2025 update to the International Classification of Diseases (ICD-11), which is a significant milestone for the global recognition of traditional medicine.

The update introduces a pioneering new module dedicated to traditional medicine conditions, marking a monumental step in the systematic tracking and global integration of traditional systems of healthcare practices related to Ayurveda, Siddha, and Unani.

This update follows the successful year-long testing and deliberations after the launch of ICD-11 TM-2 (on January 10, 2024, in New Delhi) for Ayurveda, Siddha, and Unani systems of medicine for country implementation testing. It culminates in the deliberations held at the WHO meeting at the National Institute of Health in Malaysia in November 2024. The ICD-11 TM 2 module is now officially released on the ICD-11 Blue Browser of WHO.

Also read- WHO’s 2025 ICD-11 update includes traditional medicine in health module

Powered by WPeMatico

CALIPSO Trial: OCT-Guided PCI Outperforms Angiography in Calcified Lesions

The CALIPSO randomized clinical trial has demonstrated that OCT-guided stent implantation using a predefined algorithm led to improved outcomes compared to angiography-guided PCI in patients with calcified lesions, with no added safety risks. The trial directly assessed if OCT imaging might result in increased minimal stent area (MSA), a key indicator of PCI success, by maximizing plaque preparation and lesion evaluation prior to stent implantation. The study was conducted by Nicolas A. and colleagues published in JAMA Cardiology.

Calcified plaques are a significant concern during PCI since their hardness may impede stent expansion, raise the possibility of complications, and jeopardize long-term outcomes. Although OCT offers high-resolution imaging that is able to resolve plaque composition and inform lesion preparation strategies, OCT had never before been tested under rigorous conditions against conventional angiography until now.

The CALIPSO (Calcified Lesion Intervention Planning Steered by OCT) trial was a prospective, multicenter, open-label randomized study conducted between December 2021 and June 2023, with analysis completed by April 2024. A total of 143 patients with stable coronary artery disease and moderate to severe calcification were enrolled. Following diagnostic coronary angiography, patients were randomized in a 1:1 ratio to receive either OCT-guided PCI or angiography-guided PCI.

In the OCT arm, the operators used a pre-defined algorithm of lesion management based on OCT analysis of the lesions’ characteristics. Both groups received a final OCT examination after the procedure to objectively measure the MSA, the study’s primary outcome. Secondary safety measures consisted of periprocedural myocardial infarction, dose of radiation, volume of contrast, and duration of the procedure.

Key Findings

• Of 143 randomized patients, 134 underwent the study protocol and were followed to the end in the final analysis—65 in the OCT group and 69 in the angiography group.

• Participants’ median age was 73 years (interquartile range [IQR], 66–78), and 18.7% (25 patients) were female.

• Baseline characteristics were equally distributed between groups, except for greater intravascular lithotripsy use in the OCT-directed arm (46% vs 12%; P < .001), which was an expression of better-informed plaque modification strategies.

The main outcome indicated a statistically significant difference:

• Median MSA was 6.5 mm² (IQR 5.5–8.1) in the OCT group versus 5.0 mm² (IQR 4.1–6.1) in the angiography group (P <.001).

• Rates of periprocedural complications did not differ between groups significantly, indicating that enhanced stent results were obtained without a compromise of safety.

• Procedure time and contrast volume were similar between both arms.

The CALIPSO randomized trial showed that PCI guided by OCT, in combination with systemic procedural algorithms, results in far superior stent implantation – as defined by mean stent area – compared to conventional angiography guidance in patients with calcified coronary artery disease. The findings represent strong evidence for the routine inclusion of OCT imaging as part of lesion evaluation and PCI planning in advanced calcified cases, without increased procedural risk.

Reference:

Amabile N, Rangé G, Landolff Q, et al. OCT vs Angiography for Guidance of Percutaneous Coronary Intervention of Calcified Lesions: The CALIPSO Randomized Clinical Trial. JAMA Cardiol. Published online April 30, 2025. doi:10.1001/jamacardio.2025.0741

Powered by WPeMatico